|
1
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauqer S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F and Galon J: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rajput S and Wilber A: Roles of
inflammation in cancer initiation, progression, and metastasis.
Front Biosci (Schol Ed). 2:176–183. 2010.PubMed/NCBI
|
|
3
|
Li W, Chen C, Saud SM, Geng L, Zhang G,
Liu R and Hua B: Fei-Liu-Ping ointment inhibits lung cancer growth
and invasion by suppressing tumor inflammatory microenvironment.
BMC Complement Altern Med. 14:1532014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bierie B and Moses HL: Transforming growth
factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth
Factor Rev. 21:49–59. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deng S, Hu B, Shen KP and Xu L:
Inflammation, macrophage in cancer progression and chinese herbal
treatment. J Basic Clin Pharm. 3:269–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Su Z, Sun Y, Zhu H, Liu Y, Lin X, Shen H,
Chen J, Xu W and Xu H: Th17 cell expansion in gastric cancer may
contribute to cancer development and metastasis. Immunol Res.
58:118–124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu J and Paul WE: Heterogeneity and
plasticity of T helper cells. Cell Res. 20:4–12. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirahara K, Ghoreschi K, Laurence A, Yang
XP, Kanno Y and O'Shea JJ: Signal transduction pathways and
transcriptional regulation in Th17 cell differentiation. Cytokine
Growth Factor Rev. 21:425–434. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei H, Sun R, Xiao W, Feng J, Zheng C, Xu
X and Tian Z: Type two cytokines predominance of human lung cancer
and its reverse by traditional Chinese medicine TTMP. Cell Mol
Immunol. 1:63–70. 2004.PubMed/NCBI
|
|
11
|
Dong C: Diversification of T-helper-cell
lineages: Finding the family root of IL-17-producing cells. Nat Rev
Immunol. 6:329–333. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bettelli E, Carrier Y, Gao W, Korn T,
Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal
developmental pathways for the generation of pathogenic effector
TH17 and regulatory T cells. Nature. 441:235–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang XO, Pappu BP, Nurieva R, Akimzhanov
A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, et
al: T helper 17 lineage differentiation is programmed by orphan
nuclear receptors ROR alpha and ROR gamma. Immunity. 28:29–39.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ouyang W, Kolls JK and Zheng Y: The
biological functions of T helper 17 cell effector cytokines in
inflammation. Immunity. 28:454–467. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maruyama T, Kono K, Mizukami Y, Kawaguchi
Y, Mimura K, Watanabe M, Izawa S and Fujii H: Distribution of Th17
cells and FoxP3(+) regulatory T cells in tumor-infiltrating
lymphocytes, tumor-draining lymph nodes and peripheral blood
lymphocytes in patients with gastric cancer. Cancer Sci.
101:1947–1954. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gaur P, Singh AK, Shukla NK and Das SN:
Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer
patients and their clinical significance. Hum Immunol. 75:330–337.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wrzesinski SH, Wan YY and Flavell RA:
Transforming growth factor-beta and the immune response:
Implications for anticancer therapy. Clin Cancer Res. 13:5262–5270.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jakowlew SB: Transforming growth
factor-beta in cancer and metastasis. Cancer Metastasis Rev.
25:435–457. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chu EA and Kim YJ: Laryngeal cancer:
Diagnosis and preoperative work-up. Otolaryngol Clin North Am.
41:673–695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Starmer HM, Tippet DC and Webster KT:
Effects of laryngeal cancer on voice and swallowing. Otolaryngol
Clin North Am. 41:793–818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karatzanis AD, Psychogios G, Waldfahrer F,
Kapsreiter M, Zenk J, Velegrakis GA and Iro H: Management of
locally advanced laryngeal cancer. J Otolaryngol Head Neck Surg.
43:42014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee KJ: Essential Otolaryngology Head and
Neck Surgery (7th). McGraw-Hill Medical Publishing Division. New
York: 1999. View Article : Google Scholar
|
|
24
|
Chen XM, Xu XQ, Sun K, Hallett WH, Zhao JD
and Zhang DL: NKG2D ligands expression and NKG2D-mediated
cytotoxicity in human laryngeal squamous carcinoma cells. Scand J
Immunol. 67:441–447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tian Z, Shen X, Feng H and Gao B: IL-1
beta attenuates IFN-alpha beta-induced antiviral activity and STAT1
activation in the liver involvement of proteasome-dependent
pathway. J Immunol. 165:3959–3965. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maarof G, Bouchet-Delbos L, Gary-Gouy H,
Durand-Gasselin I, Krzysiek R and Dalloul A: Interleukin-24
inhibits the plasma cell differentiation program in human germinal
center B cells. Blood. 115:1718–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaseviciene L, Gurevicius R, Obelenis V,
Cicenas S and Juozulynas A: Trends in laryngeal cancer incidence in
Lithuania: A future perspective. Int J Occup Med Environ Health.
17:473–477. 2004.PubMed/NCBI
|
|
29
|
Lu ST, Wei KR, Yu BH, Chen Z, Liang Z,
Fang F and Zheng WB: Analysis of laryngeal cancer incidence rate in
Zhongshan City in 1970–1999. Xian Dai Zhong Liu Yi Xue. 12:158–160.
2004.
|
|
30
|
Hoffman HT, Porter K, Karnell LH, Cooper
JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A and Robinson RA:
Laryngeal cancer in the United States: Changes in demographics,
patterns of care, and survival. Laryngoscope. 116(9 Pt 2 Suppl
111): S1–S13. 2006. View Article : Google Scholar
|
|
31
|
Gourin CG, Conger BT, Sheils WC, Bilodeau
PA, Coleman TA and Porubsky ES: The effect of treatment on survival
in patients with advanced laryngeal carcinoma. Laryngoscope.
119:1312–1317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hashibe M, Boffetta P, Zaridze D, Shangina
O, Szeszenia-Dabrowska N, Mates D, Fabiánová E, Rudnai P and
Brennan P: Contribution of tobacco and alcohol to the high rates of
squamous cell carcinoma of the supraglottis and glottis in Central
Europe. Am J Epidemiol. 165:814–820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shangina O, Brennan P, Szeszenia-Dabrowska
N, Mates D, Fabiánová E, Fletcher T, t'Mannetje A, Boffetta P and
Zaridze D: Occupational exposure and laryngeal and hypopharyngeal
cancer risk in Central and eastern Europe. Am J Epidemiol.
164:367–375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma L, Liang Y, Fang M, Guan Y, Si Y, Jiang
F and Wang F: The cytokines (IFN-gamma, IL-2, IL-4, IL-10, IL-17)
and Treg cytokine (TGF-beta1) levels in adults with immune
thrombocytopenia. Pharmazie. 69:694–697. 2014.PubMed/NCBI
|
|
35
|
Li P, Spolski R, Liao W and Leonard WJ:
Complex interactions of transcription factors in mediating cytokine
biology in T cells. Immunol Rev. 261:141–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma W, Wang K, Du J, Luan J and Lou G:
Multi-dose parecoxib provides an immune protective effect by
balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines
following laparoscopy in patients with cervical cancer. Mol Med
Rep. 11:2999–3008. 2015.PubMed/NCBI
|
|
37
|
Murugaiyan G and Saha B: Protumor vs
antitumor functions of IL-17. J Immunol. 183:4169–4175. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mosmann TR and Sad S: The expanding
universe of T-cell subsets: Th1, Th2 and more. Immunol Today.
17:138–146. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yamamura M, Modlin RL, Ohmen JD and Moy
RL: Local expression of antiinflammatory cytokines in cancer. J
Clin Invest. 91:1005–1010. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oshikawa K, Yanagisawa K, Ohno S, Tominaga
S and Sugiyama Y: Expression of ST2 in helper T lymphocytes of
malignant pleural effusions. Am J Respir Crit Care Med.
165:1005–1009. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen YM, Yang WK, Whang-Peng J, Tsai CM
and Perng RP: An analysis of cytokine status in the serum and
effusions of patients with tuberculous and lung cancer. Lung
Cancer. 31:25–30. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kharkevitch DD, Seito D, Balch GC, Maeda
T, Balch CM and Itoh K: Characterization of autologous
tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes
from a patient with metastatic melanoma. Int J Cancer. 58:317–323.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chtanova T and Mackay CR: T cell effector
subsets: Extending the Th1/Th2 paradigm. Adv Immunol. 78:233–266.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Farrag TY, Koch WM, Cummings CW,
Goldenberg D, Abou-Jaoude PM, Califano JA, Flint PW, Webster K and
Tufano RP: Supracricoid laryngectomy outcomes: The Johns Hopkins
experience. Laryngoscope. 117:129–132. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Page C, Mortuaire G, Mouawad F, Ganry O,
Darras J, Pasquesoone X and Chevalier D: Supracricoid laryngectomy
with cricohyoidoepiglottopexy (CHEP) in the management of laryngeal
carcinoma: Oncologic results. A 35-year experience. Eur Arch
Otorhinolaryngol. 270:1927–1932. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Agarwal S, Misra R and Aggarwal A:
Interleukin 17 levels are increased in juvenile idiopathic
arthritis synovial fluid and induce synovial fibroblasts to produce
proinflammatory cytokines and matrix metalloproteinases. J
Rheumatol. 35:515–519. 2008.PubMed/NCBI
|
|
47
|
Gu Y, Hu X, Liu C, Qv X and Xu C:
Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and
tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol.
142:109–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Numasaki M, Watanabe M, Suzuki T,
Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze
MT, Kolls JK and Sasaki H: IL-17 enhances the net angiogenic
activity and in vivo growth of human non-small cell lung cancer in
SCID mice through promoting CXCR-2-dependent angiogenesis. J
Immunol. 175:6177–6189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nabeshima K, Inoue T, Shimao Y and
Sameshima T: Matrix metalloproteinases in tumor invasion: Role for
cell migration. Pathol Int. 52:255–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li A, Dubey S, Varney ML, Dave BJ and
Singh RK: IL-8 directly enhanced endothelial cell survival,
proliferation and matrix metalloproteinases production and
regulated angiogenesis. J Immunol. 170:3369–3376. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nam JS, Terabe M, Kang MJ, Chae H, Voong
N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, et al:
Transforming growth factor beta subverts the immune system into
directly promoting tumor growth through interleukin-17. Cancer Res.
68:3915–3923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kryczek I, Wei S, Szeliga W, Vatan L and
Zou W: Endogenous IL-17 contributes to reduced tumor growth and
metastasis. Blood. 114:357–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Muranski P, Boni A, Antony PA, Cassard L,
Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K,
et al: Tumor-specific Th17-polarized cells eradicate large
established melanoma. Blood. 112:362–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cirée A, Michel L, Camilleri-Bröet S,
Louis Jean F, Oster M, Flageul B, Senet P, Fossiez F, Fridman WH,
Bachelez H and Tartour E: Expression and activity of IL-17 in
cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Int J Cancer. 112:113–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Garcia-Hernandez Mde L, Hamada H, Reome
JB, Misra SK, Tighe MP and Dutton RW: Adoptive transfer of
tumor-specific Tc17 effector T cells controls the growth of B16
melanoma in mice. J Immunol. 184:4215–4227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Honorati MC, Neri S, Cattini L and
Facchini A: IL-17 enhances the susceptibility of U-2 OS
osteosarcoma cells to NK cell lysis. Clin Exp Immunol. 133:344–349.
2003. View Article : Google Scholar : PubMed/NCBI
|
